Identify patients based on histological and molecular profiles
Review the importance of primary breast cancer subtypes when discussing trial eligibility with your patients (including men):
ER+/HER2- BREAST CANCER (estrogen receptor positive - sometimes referred to as HR+ or Hormone Receptor positive / human epidermal growth factor receptor 2-positive)
This is a subtype of breast cancer that cancer cells test positive for a receptor proteins that bind to estrogen (ER) and test negative for a protein called human epidermal growth factor receptor 2 (HER2). This subtype of breast cancer is sensitive to treatment with anti-estrogen hormone (endocrine) therapies.
HER2+ BREAST CANCER (human epidermal growth factor receptor 2-positive)
This is a subtype of breast cancer that cancer cells test positive for HER2. This protein promotes the growth of cancer cells. HER2-positive breast cancers tend to be aggressive and are sensitive to HER2-directed therapies.
TRIPLE-NEGATIVE BREAST CANCER (ER-, PR-, HER2-)
This is a subtype of breast cancer that cancer cells test negative for ER, a receptor protein that binds to progesterone (PR) and HER2. This subtype of breast cancer tends to grow and spread faster than other types of breast cancers and are not sensitive to endocrine therapies and HER2-directed therapies.
Your insights help patients understand their options
An open dialogue with your patients may give them a better understanding of clinical trials. By starting a conversation based on your expert guidance, patients gain the knowledge to confidently make choices regarding the next step in their care.
When referring a patient to a study, please be assured that you will continue to provide primary care for the patient. Study staff will provide study-related care only.
If you have a patient you think may qualify for a clinical trial, you can discuss patient eligibility by referring them to a principal investigator.
Click the links below to review complete eligibility criteria, study site locations, and contact information for these studies.
1. AACR Publications/Cancer Research/Abstract 4191: The Worldwide female breast cancer incidence and survival, 2018; Zoubida Zaidi and Hussain Adlane Dib; DOI: 10.1158/1538-7445. AM2019-4191. Published July 2019. 2. ABC Global Alliance. Breast cancer worldwide. Available at: https://www.abcglobalalliance.org/articles/breast-cancer-worldwide/. Accessed February 24, 2020. 3. Schmid P, Park YH, Muñoz-Couselo E, et al. Pembrolizumab (Pembro) + chemotherapy (Chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2017;35(suppl_15):556-6. 4. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. The New England Journal of Medicine. 2018;379;2108-21. 5. Nanda R, Liu MC, Yau C, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY2. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2017;35(suppl_15):506. 6. Loibl S, Untch M, Burchardi N, et al. Randomized Phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2018;36(15_suppl):104. 7. Pennisi A, Kieber-Emmons T, Makhoul I, Hutchins L. Relevance of pathological complete response after neoadjuvant therapy for breast cancer. Breast Cancer: Basic and Clinical Research. 2016;10:103-6. 8. Somkin CP, Altschuler A, Ackerson L, et al. Organizational barriers to physician participation in cancer clinical trials. Am J Manag Care. 2005;11:413-421.